(UroToday.com) Dr Tamara Bavendam was given the SUFU Lifetime Achievement award in recognition of an outstanding career in urology. She had previously received SUFU’s Distinguished Service award. In accepting the reward, Dr. Bavendam reflected on what she termed “my unusual career”.
Application Based on Objective Response Rate From Phase 2 Trial Evaluating Belzutifan in Patients With Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma New Filing Further Strengthens Merck’s Expanding and Diverse Oncology Portfolio San Francisco, CA (UroToday.com) — Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has […]
Oliver Sartor: Hi, I’m Dr. Oliver Sartor. I’m a Professor of Medicine in urology at Tulane University and Medical Director of Tulane Cancer Center. I’m delighted to be joined here today with Alicia Morgans, who is at Northwestern University and has so many titles, they are hard to remember. So with that being said, I […]
Currently, ~95% of patients with testicular germ cell tumour (TGCT) are cured, resulting in an increasing number of TGCT survivors. Although cured, these men face potential late adverse effects and reduced quality of life.
To assess trends in incidence, disease management and survival of upper urinary tract urothelial carcinoma (UTUC) in the Netherlands. Patients diagnosed with primary UTUC in the Netherlands between 1993 and 2017 were identified through the population-based Netherlands Cancer Registry (NCR).
To determine, using testicular germ cell cancer screening as an example, whether screening can also be effective for cancers with a good prognosis. Based on the Dutch incidence, stage distribution, and survival and mortality data of testicular germ cell cancer, we developed a microsimulation model.
Interleukin (IL)-10 has anti-inflammatory and CD8+ T-cell-stimulating properties. Pegilodecakin (pegylated recombinant human IL-10) induces intra-tumoral antigen specific CD8+T-cells and upregulates IFNγ and Major Histocompatibility Complex (MHC) I and II.
Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly understood. We characterize the single-cell transcriptomes of cancer and immune cells from metastatic RCC patients before or after ICB exposure.
If magnetic resonance imaging (MRI) mitigates overdiagnosis of prostate cancer while improving the detection of clinically significant cases, including MRI in a screening program for prostate cancer could be considered.
OATP1B3 is expressed de novo in primary prostate cancer tissue and to a greater degree in prostate cancer metastases. Gadoxetate disodium is a substrate of OATP1B3, and its uptake has been shown to correlate with OATP1B3 expression in other cancers.
